Evidence map›Paper›PMID 37066414›Full record

ArticleResearch square2023

Oral TGF-βR1 inhibitor Vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity.

Sung Hee Choi, Jay Myers, Suzanne Tomchuck, Melissa Bonner, Saada Eid, Daniel Kingsley, Kristen VanHeyst, Seong-Jin Kim, Byung-Gyu Kim, Alex Y Huang

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sung Hee ChoiDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Jay MyersDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.ORCID 0000-0003-2574-0438
Suzanne TomchuckDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Melissa BonnerDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Saada EidDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Daniel KingsleyDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Kristen VanHeystDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Seong-Jin KimMedPacto Inc., Seoul, 06668, Republic of Korea.
Byung-Gyu KimDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Alex Y HuangDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.ORCID 0000-0002-5701-4521
Case Western Reserve University · USMedpace (United States) · US

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARK R CHANCE · 1987 to 2026
$142.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
TRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2M
RESEARCH ONCOLOGY TRAINING GRANTT32CA059366 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI JACKSON, MARK W. · 1993 to 2025
$5.5M
Characterizing a new antibody targeting growth-arrested breast cancer cellsR03CA230840 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 2018 to 2019
$160k
NCI NIH HHS K12 CA076917NCI NIH HHS P30 CA043703NCI NIH HHS R03 CA230840NCI NIH HHS T32 CA059366NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

Osteosarcoma (OS) is an aggressive malignant bone cancer, with refractory and metastatic disease remaining a significant challenge. Transforming growth factor-β1 (TGF-β) is a potent immune suppressive cytokine in OS and the TGF-β is increased in the sera of OS patients and this increase is associated with high-grade OS and lung metastases. Therefore, blocking TGF-β1 signaling may be a novel therapy for OS treatment. Here we show that blocking TGF-β1 signaling using TGF-βR1 inhibitor, Vactosertib, significantly inhibited OS proliferation

Indexed as

c-MycOsteosarcomapulmonary metastasisTGF-β1tumor microenvironment (TME)

Identifiers

PMID37066414
PMCPMC10104208
OpenAlexW4362585514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.